Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $75.44.

A number of equities research analysts have recently weighed in on ELVN shares. Zacks Research downgraded Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Mizuho raised their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Stifel Nicolaus raised their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Finally, Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th.

Enliven Therapeutics Stock Up 2.5%

Shares of Enliven Therapeutics stock opened at $44.78 on Thursday. The firm has a market cap of $3.28 billion, a P/E ratio of -26.81 and a beta of 0.24. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. The business has a 50-day moving average price of $49.28 and a 200 day moving average price of $42.38.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts anticipate that Enliven Therapeutics will post -1.79 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Mika K. Derynck sold 158,795 shares of Enliven Therapeutics stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the transaction, the director directly owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the sale, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. This represents a 13.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 189,849 shares of company stock valued at $11,054,870. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its position in shares of Enliven Therapeutics by 37.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,369 shares of the company’s stock worth $622,000 after acquiring an additional 3,676 shares during the last quarter. Sterling Capital Management LLC increased its holdings in shares of Enliven Therapeutics by 1,180.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock worth $88,000 after acquiring an additional 1,771 shares during the period. Assenagon Asset Management S.A. lifted its position in Enliven Therapeutics by 276.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock valued at $52,898,000 after purchasing an additional 847,399 shares during the last quarter. First Light Asset Management LLC lifted its position in Enliven Therapeutics by 574.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock valued at $69,058,000 after purchasing an additional 1,158,883 shares during the last quarter. Finally, Tidal Investments LLC boosted its stake in Enliven Therapeutics by 27.7% during the 2nd quarter. Tidal Investments LLC now owns 60,694 shares of the company’s stock valued at $3,080,000 after purchasing an additional 13,179 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.